. 2021 Jul 9;112(9):3598–3606. doi: 10.1111/cas.15019

TABLE 3.

Comparison of the treatment outcomes after hypofractionated radiotherapy at approximately 5 years of follow‐up

Type of radiation	Dose (Gy)/no. of fractions	BED		No. of pts	Median f/u (years)	5‐year biochemical relapse‐free rate (%)			5‐year toxicity rates (%)
		α/β				5‐year biochemical relapse‐free rate (%)			Late GI		Late GU
		1.5	3.0			Low	Int.	High	Grade 2	Grade 3	Grade 2	Grade 3
X‐ray radiotherapy
CHHiP⁵	74/37	172	123	1065	5.2	96.7	86.8	86.5	13.7^a	2	9.1^a	3
	60/20	180	120	1074		96.6	90.2	84.2	11.9^a	3	11.7^a	6
	57/19	171	114	1077		90.9	86	78.3	11.3^a	4	6.6^a	3
Fox Chase⁶	78/36	182	130	152	5.7	79.6^b			20.5^a	2^c	13.4^a	3.3^c
Fox Chase⁶	70.2/26	196	133	151	5.7	76.7^b			16.1^a	2^c	21.5^a	4^c
RTOG 0415⁷	73.8/41	162	118	543	5.8	91.9	—	—	11.4^c	2.6^c, ^d	20.5^c	2.3^c, ^d
RTOG 0415⁷	70/28	187	128	550	5.8	94.3	—	—	18.3^c	4.1^c	26.2^c	3.5^c
HYPRO⁸, ⁹	78/39	182	130	410	5.0		77.1^b, ^g		17^a (3y)	2.6^e (3y)	39^a (3y)	19^e (3y)
HYPRO⁸, ⁹	64.6/19	211	138	410	5.0		80.5^b, ^g		21.9^a (3y)	3.3^e (3y)	41.3^a (3y)	12.9^e (3y)
PROFIT¹⁰	78/39	182	130	608	6.0	85%^b, ^f, ^g		—	11^c	2.9^c, ^d, ^e	19	3.0^c, ^d, ^e
PROFIT¹⁰	60/20	180	120	598	6.0	85%^b, ^f, ^g		—	7.4^c	1.5^c	20	2.2^c, ^d, ^e
MD Anderson¹¹	75.6/42	166	121	102	8.5	91.7^f		—	4^c (8y)	1^c (8y)	15^c (8y)	1^c (8y)
MD Anderson¹¹	72/30	187	130	104	8.5	91.8^f		—	10^c (8y)	2^c (8y)	15^c (8y)	0
Carbon‐ion radiotherapy
Okada (passive)¹⁶	66 (RBE)/20	211	138	250	4.9	90	97	88	3.2^c	0	15.2	0
	63 (RBE)/20	193	128	216					2.3^c	0	8.2	0
	57.6 (RBE)/16	195	127	274					1.5^c	0	5.0	0
Kawamura (passive)²⁹	57.6 (RBE)/16	195	127	304	5.0	91.7	93.4	92	0.3^c	0	9^c	0.3^c
Present study	51.6 (RBE)/12	200	126	256	7.0	95.1	90.9	91.1	0.4	0	6.3	0

Abbreviations: BED, biologically effective dose; fr, fraction; GI, gastrointestinal, GU, genitourinary; Gy, gray; int., intermediate; Pt, patient.

^{^a}

Rate of ≥grade 2 toxicities.

^{^b}

Not available in each risk group.

^{^c}

Crude rate.

^{^d}

Including one case of grade 4 toxicity.

^{^e}

Rate of ≥grade 3 toxicities.

^{^f}

Almost all patients were categorized as low or intermediate risk.

^{^g}

Biochemical relapse‐free survival rate.